Newron Pharmaceuticals S.p.A.
NWPHF · OTC
12/31/2024 | 6/30/2024 | 12/31/2023 | 6/30/2023 | |
|---|---|---|---|---|
| Revenue | $48 | $3 | $4 | $5 |
| % Growth | 1,308.4% | -4.4% | -35.1% | – |
| Cost of Goods Sold | $0 | $0 | $0 | $0 |
| Gross Profit | $48 | $3 | $4 | $5 |
| % Margin | 100% | 100% | 100% | 100% |
| R&D Expenses | $7 | $6 | $8 | $6 |
| G&A Expenses | $3 | $5 | $3 | $4 |
| SG&A Expenses | $3 | $5 | $3 | $4 |
| Sales & Mktg Exp. | $0 | $0 | $0 | $0 |
| Other Operating Expenses | $4 | $0 | -$0 | $0 |
| Operating Expenses | $14 | $11 | $11 | $10 |
| Operating Income | $34 | -$8 | -$7 | -$4 |
| % Margin | 70.6% | -225.5% | -205.5% | -78.4% |
| Other Income/Exp. Net | -$3 | -$2 | -$2 | -$3 |
| Pre-Tax Income | $31 | -$10 | -$9 | -$7 |
| Tax Expense | $6 | $0 | $0 | $0 |
| Net Income | $25 | -$10 | -$9 | -$7 |
| % Margin | 52.9% | -280.5% | -260.3% | -126.5% |
| EPS | 1.36 | -0.51 | -0.52 | -0.39 |
| % Growth | 366.7% | 1.9% | -33.3% | – |
| EPS Diluted | 1.36 | -0.51 | -0.52 | -0.39 |
| Weighted Avg Shares Out | 19 | 19 | 18 | 18 |
| Weighted Avg Shares Out Dil | 19 | 19 | 18 | 18 |
| Supplemental Information | – | – | – | – |
| Interest Income | $0 | $0 | $2 | $2 |
| Interest Expense | $4 | $0 | $0 | $0 |
| Depreciation & Amortization | $0 | $0 | $0 | $0 |
| EBITDA | $34 | -$8 | -$7 | -$4 |
| % Margin | 69.9% | -222.7% | -204.5% | -76.5% |